Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, Bechstein WO, Neumann UP, Waldschmidt D, Boeck S, Moosmann N, Reinacher-Schick AC, Golcher H, Adler W, Semrau S, Lubgan D, Kallies A, Hecht M, Tischoff I, Tannapfel A, Frey B, Oettle H (2026)


Publication Type: Journal article, Erratum

Publication year: 2026

Journal

Book Volume: 44

Pages Range: 430-430

Journal Issue: 5

DOI: 10.1200/JCO-25-03004

Authors with CRIS profile

How to cite

APA:

Fietkau, R., Ghadimi, M., Grützmann, R., Wittel, U.A., Jacobasch, L., Uhl, W.,... Oettle, H. (2026). Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. Journal of Clinical Oncology, 44(5), 430-430. https://doi.org/10.1200/JCO-25-03004

MLA:

Fietkau, Rainer, et al. "Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial." Journal of Clinical Oncology 44.5 (2026): 430-430.

BibTeX: Download